You have 9 free searches left this month | for more free features.

City

Ann Arbor (1)

Boston (1)

Condition

Bile Duct Cancer (1)

Cholangiocarcinoma (1)

Cholangiocarcinoma Metastatic (1)

Cholangiocarcinoma Non-resectable (1)

Hepatocellular Carcinoma (HCC) (1)

Metastatic Intrahepatic Cholangiocarcinoma (1)

Unresectable Hepatocellular Carcinoma (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Dana-Farber Cancer Institute (1)

University of Michigan Rogel Cancer Center (1)

Collaborator

AstraZeneca (1)

Department of Health and Human Services (1)

Sirtex Medical (1)

Intervention

yttrium-90 (2)

cisplatin (1)

durvalumab (1)

gemcitabine (1)

pet/ct (1)

selective internal radiation therapy (1)

stereotactic body radiation therapy (1)

therasphere (1)

Study Documents

Intervention Type

drug (2)

radiation (2)

device (1)

diagnostic test (1)

Funder Type

Other (2)

Study Type

Interventional (2)

yttrium-90

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable Trial in Boston (Gemcitabine, Cisplatin, Durvalumab)

Not yet recruiting

Bile Duct Cancer
+4 more

Gemcitabine
+3 more

Boston, Massachusetts

Beth Israel Deaconess Medical Center

Jan 23, 2023

Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma Trial in Ann Arbor (drug, device, radiation, diagnostic

Recruiting

Hepatocellular Carcinoma (HCC)
Unresectable Hepatocellular Carcinoma

Yttrium-90
+4 more

Ann Arbor, Michigan

University of Michigan Rogel Cancer Center

Dec 16, 2021